Compare Kinder Morgan Inc (KMI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Sana Biotechnology Inc — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Kinder Morgan Inc is far larger — about 85.8× Sana Biotechnology Inc's market cap, and Kinder Morgan Inc pays a 3.66% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and Sana Biotechnology Inc for 23 Days on average.
| KMI | SANA | |
|---|---|---|
Market Cap | $71.81B | $836.71M |
Volume | 16,921,908 | 4,507,444 |
Sector | Energy | Health |
52-Week High | $34.31 | $5.92 |
52-Week Low | $25.84 | $2.68 |
Typical Hold Time | 150 Days | 23 Days |
Enterprise Value | $103.86B | $749.96M |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.25, up 1.35% with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, posting 18% net income margin growth in 2025. Analyst consensus shows mixed sentiment with 47% buy ratings and a $37.20 price target, representing 15% upside potential. Recent news highlights the company's $6-7B growth runway from Southeast gas demand and data center expansion.
KMI offers investors stable fee-based revenue from energy infrastructure with a compelling dividend yield. The stock presents growth potential from natural gas demand trends but faces risks from energy market volatility and high debt levels. Current valuation metrics appear reasonable given the company's profitability and growth backlog, though technical indicators show some overbought conditions near-term.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
